Nicole M. Armstrong

Olipudase alfa enzyme replacement therapy for acid sphingomyelinase deficiency (ASMD): sustained improvements in clinical outcomes after 6.5 years of treatment in adults

R. Lachmann, G. Diaz, M. Wasserstein, 2023, Orphanet Journal of Rare Diseases.

Isatuximab plus carfilzomib and dexamethasone in patients with early versus late relapsed multiple myeloma: IKEMA subgroup analysis.

M. Mohty, P. Moreau, X. Leleu, 2022, Haematologica.

Isatuximab plus carfilzomib and dexamethasone in patients with early versus late relapsed multiple myeloma: IKEMA subgroup analysis

M. Mohty, P. Moreau, X. Leleu, 2023, Haematologica.

P916: LONG-TERM OUTCOMES WITH ISATUXIMAB-CARFILZOMIB-DEXAMETHASONE (ISA-KD) IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH 1Q21+ STATUS: UPDATED RESULTS FROM THE PHASE 3 IKEMA STUDY

P. Moreau, T. Facon, K. Yong, 2023, HemaSphere.